These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 22387542)

  • 1. Rapamycin enhances docetaxel-induced cytotoxicity in a androgen-independent prostate cancer xenograft model by survivin downregulation.
    Morikawa Y; Koike H; Sekine Y; Matsui H; Shibata Y; Ito K; Suzuki K
    Biochem Biophys Res Commun; 2012 Mar; 419(3):584-9. PubMed ID: 22387542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lenalidomide enhances the anti-prostate cancer activity of docetaxel in vitro and in vivo.
    Henry JY; Lu L; Adams M; Meyer B; Bartlett JB; Dalgleish AG; Galustian C
    Prostate; 2012 Jun; 72(8):856-67. PubMed ID: 21968939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methylseleninic acid enhances taxane drug efficacy against human prostate cancer and down-regulates antiapoptotic proteins Bcl-XL and survivin.
    Hu H; Li GX; Wang L; Watts J; Combs GF; Lü J
    Clin Cancer Res; 2008 Feb; 14(4):1150-8. PubMed ID: 18281549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual PI3K/mTOR inhibitor NVP-BEZ235 sensitizes docetaxel in castration resistant prostate cancer.
    Yasumizu Y; Miyajima A; Kosaka T; Miyazaki Y; Kikuchi E; Oya M
    J Urol; 2014 Jan; 191(1):227-34. PubMed ID: 23954373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapamycin enhances the susceptibility of both androgen-dependent and -independent prostate carcinoma cells to docetaxel.
    Liu QJ; Xu XH; Shang DH; Tian Y; Lü WC; Zhang YH
    Chin Med J (Engl); 2010 Feb; 123(3):356-60. PubMed ID: 20193259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of tumor growth and sensitization to chemotherapy by RNA interference targeting interleukin-6 in the androgen-independent human prostate cancer PC3 model.
    Sakai I; Miyake H; Terakawa T; Fujisawa M
    Cancer Sci; 2011 Apr; 102(4):769-75. PubMed ID: 21214673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A combination of desmopressin and docetaxel inhibit cell proliferation and invasion mediated by urokinase-type plasminogen activator (uPA) in human prostate cancer cells.
    Sasaki H; Klotz LH; Sugar LM; Kiss A; Venkateswaran V
    Biochem Biophys Res Commun; 2015 Aug; 464(3):848-54. PubMed ID: 26182875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High efficacy of docetaxel with and without androgen deprivation and estramustine in preclinical models of advanced prostate cancer.
    Fizazi K; Sikes CR; Kim J; Yang J; Martinez LA; Olive MC; Logothetis CJ; Navone NM
    Anticancer Res; 2004; 24(5A):2897-903. PubMed ID: 15517894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-cancer efficacy of SREBP inhibitor, alone or in combination with docetaxel, in prostate cancer harboring p53 mutations.
    Li X; Wu JB; Chung LW; Huang WC
    Oncotarget; 2015 Dec; 6(38):41018-32. PubMed ID: 26512780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of docetaxel with or without estramustine phosphate versus mitoxantrone in androgen dependent and independent human prostate cancer xenografts.
    Oudard S; Legrier ME; Boyé K; Bras-Gonçalves R; De Pinieux G; De Cremoux P; Poupon MF
    J Urol; 2003 May; 169(5):1729-34. PubMed ID: 12686819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 3,3'-Diindolylmethane enhances taxotere-induced apoptosis in hormone-refractory prostate cancer cells through survivin down-regulation.
    Rahman KM; Banerjee S; Ali S; Ahmad A; Wang Z; Kong D; Sakr WA
    Cancer Res; 2009 May; 69(10):4468-75. PubMed ID: 19435906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Everolimus (RAD001) sensitizes prostate cancer cells to docetaxel by down-regulation of HIF-1α and sphingosine kinase 1.
    Alshaker H; Wang Q; Kawano Y; Arafat T; Böhler T; Winkler M; Cooper C; Pchejetski D
    Oncotarget; 2016 Dec; 7(49):80943-80956. PubMed ID: 27821815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concurrent and sequential administration of chemotherapy and the Mammalian target of rapamycin inhibitor temsirolimus in human cancer cells and xenografts.
    Fung AS; Wu L; Tannock IF
    Clin Cancer Res; 2009 Sep; 15(17):5389-95. PubMed ID: 19706800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Azacitidine improves antitumor effects of docetaxel and cisplatin in aggressive prostate cancer models.
    Festuccia C; Gravina GL; D'Alessandro AM; Muzi P; Millimaggi D; Dolo V; Ricevuto E; Vicentini C; Bologna M
    Endocr Relat Cancer; 2009 Jun; 16(2):401-13. PubMed ID: 19153211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular chemotherapy and chemotherapy: a new front against late-stage hormone-refractory prostate cancer.
    Singh PP; Joshi S; Russell PJ; Verma ND; Wang X; Khatri A
    Clin Cancer Res; 2011 Jun; 17(12):4006-18. PubMed ID: 21531822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts.
    Wu L; Birle DC; Tannock IF
    Cancer Res; 2005 Apr; 65(7):2825-31. PubMed ID: 15805283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Docetaxel loaded oleic acid-coated hydroxyapatite nanoparticles enhance the docetaxel-induced apoptosis through activation of caspase-2 in androgen independent prostate cancer cells.
    Luo Y; Ling Y; Guo W; Pang J; Liu W; Fang Y; Wen X; Wei K; Gao X
    J Control Release; 2010 Oct; 147(2):278-88. PubMed ID: 20655966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor activity of YM155, a selective small-molecule survivin suppressant, alone and in combination with docetaxel in human malignant melanoma models.
    Yamanaka K; Nakahara T; Yamauchi T; Kita A; Takeuchi M; Kiyonaga F; Kaneko N; Sasamata M
    Clin Cancer Res; 2011 Aug; 17(16):5423-31. PubMed ID: 21737502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relaxin receptor antagonist AT-001 synergizes with docetaxel in androgen-independent prostate xenografts.
    Neschadim A; Pritzker LB; Pritzker KP; Branch DR; Summerlee AJ; Trachtenberg J; Silvertown JD
    Endocr Relat Cancer; 2014 Jun; 21(3):459-71. PubMed ID: 24812057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genistein combined polysaccharide enhances activity of docetaxel, bicalutamide and Src kinase inhibition in androgen-dependent and independent prostate cancer cell lines.
    Burich RA; Holland WS; Vinall RL; Tepper C; White RW; Mack PC
    BJU Int; 2008 Nov; 102(10):1458-66. PubMed ID: 18565171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.